Related Experiment Video
Updated: Sep 3, 2026

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy (rNAION)
Published on: November 20, 2016
GLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy: an illustrative case
Ali Devebacak1, Dilek Top Karti2, Busra Sutas1
1Department of Ophthalmology, Dokuz Eylul University, İzmir, Türkiye.
Clinical Relevance:
Non-arteritic anterior ischaemic optic neuropathy may occur following exposure to glucagon-like peptide-1 receptor agonists, although a causal relationship has not been established.
Background:
Recent evidence has raised concern regarding a possible association between glucagon-like peptide-1 receptor agonists and non-arteritic anterior ischaemic optic neuropathy. We describe an illustrative case occurring in a younger patient without diabetes mellitus or hypertension.
Methods:
A 37-year-old woman with obesity and insulin resistance developed painless unilateral visual loss following three once-weekly doses of semaglutide, all administered before symptom onset. Clinical examination, multimodal ophthalmic imaging, visual field testing, neuroimaging, and laboratory investigations were performed.
Results:
The right eye showed optic disc oedema, a dense inferior altitudinal visual field defect, and marked peripapillary retinal nerve fibre layer thickening, supporting a diagnosis of non-arteritic anterior ischaemic optic neuropathy. Investigations excluded alternative inflammatory, demyelinating, infectious, arteritic, compressive, and pseudopapilloedema-related causes. At three months, the optic disc oedema had resolved with residual pallor, while the visual field defect persisted.
Conclusions:
Although causality cannot be established from a single case, recent glucagon-like peptide-1 receptor agonist exposure may be relevant when evaluating atypical optic neuropathy in younger patients.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
